Assessment of belatacept-mediated costimulation blockade through evaluation of CD80/86-receptor saturation

Transplantation

Volumn 87, Issue 6, 2009, Pages 926-933

  Latek, Robert ^a   Fleener, Catherine ^a   Lamian, Vahideh ^a   Kulbokas, Edward ^a   Davis, Patricia M ^a   Suchard, Suzanne J ^a   Curran, Mark ^a   Vincenti, Flavio ^b   Townsend, Robert ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b UCSF Medical Center at Parnassus   (United States)

Author keywords

Belatacept; CD80 receptor; CD86 receptor; Receptor occupancy; Renal transplant

Indexed keywords

B7 ANTIGEN; BELATACEPT; CD 80 RECEPTOR; CD 86 RECEPTOR; CD86 ANTIGEN; CYCLOSPORIN; CYCLOSPORIN A; LYMPHOCYTE ANTIGEN RECEPTOR; UNCLASSIFIED DRUG; ABATACEPT; ANTIBODY CONJUGATE; HLA ANTIGEN; IMMUNOSUPPRESSIVE AGENT; LEUKOCYTE ANTIGEN;

ANTIGEN BINDING; ANTIGEN PRESENTING CELL; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG RECEPTOR BINDING; FLOW CYTOMETRY; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR OCCUPANCY; T LYMPHOCYTE ACTIVATION; ANIMAL; DENDRITIC CELL; DRUG EFFECT; GRAFT REJECTION; IMMUNOLOGY; KIDNEY TRANSPLANTATION; LYMPHOCYTE ACTIVATION; MONOCYTE; RANDOMIZATION; SHEEP;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD80; ANTIGENS, CD86; CYCLOSPORINE; DENDRITIC CELLS; FLOW CYTOMETRY; GRAFT REJECTION; HLA ANTIGENS; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LYMPHOCYTE ACTIVATION; MONOCYTES; RANDOM ALLOCATION; RECEPTORS, ANTIGEN, T-CELL; SHEEP;

EID: 65549169583     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31819b5a58     Document Type: Article

References (13)

1. Larsen CP, Knechtle SJ, Adams A, et al. A new look at blockade of T-cell costimulation: A therapeutic strategy for long-term maintenance immunosuppression. Am J Transplant 2006; 6(5 Pt 1): 876.
2. Bretscher P, Cohn M. A theory of self-nonself discrimination. Science 1970; 169: 1042.
3. McAdam AJ, Schweitzer AN, Sharpe AH. The role of B7 co-stimulation in activation and differentiation of CD4-and CD8-T cells. Immunol Rev 1998; 165: 231.
4. KimKS,DentonMD,ChandrakerA,et al.CD28-B7-mediatedTcellcostimulation in chronic cardiac allograft rejection: Differential role of B7-1 in initiation versus progression of graft arteriosclerosis.AmJ Pathol 2001; 158: 977.
5. Alegre ML, Frauwirth KA, Thompson CB. T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol 2001; 1: 220.
6. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995; 182: 459.
7. Chambers CA, Kuhns MS, Allison JP. Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates primary and secondary peptide-specific CD4(-) T cell responses. Proc Natl Acad Sci U S A 1999; 96: 8603.
8. Larsen CP, Pearson TC, Adams AB, et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005; 5: 443.
9. Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353: 770.
10. BENEFIT. Available at: http://www.clinicaltrials.gov/ct2/show/ NCT00256750? term-belatacept&rank-5. Accessed July 2008.
11. Bernard F, Jaleco S, Dardalhon V, et al. Ex vivo isolation protocols differentially affect the phenotype of human CD4- T cells. J Immunol Methods 2002; 271: 99.
12. Xiang J, Gu X, Qian S, et al. Graded function of CD80 and CD86 in initiation of T-cell immune response and cardiac allograft survival. Transpl Int 2008; 21: 163.
13. Bluestone JA, Liu W, Yabu JM, et al. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am J Transplant 2008; 8: 2086.